OMERACT 过滤器 2.1：健康干预研究中结局测量的概念框架的详细说明。
OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies.
机构信息
From the Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit; Department of Medical Humanities, VU University Medical Centre/EMGO+ institute, Amsterdam, the Netherlands; Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario; McGill Centre for Outcomes Research and Evaluation, Montreal, Quebec, Canada; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; Medicine Service, VA Medical Center; Department of Medicine, School of Medicine, University of Alabama; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Saint-Quentin en Yvelines; Sorbonne Université; Pitié Salpêtrière hospital, AP-HP, Rheumatology Department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research; Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia.
M. Boers, MD, PhD, Professor of Clinical Epidemiology, Amsterdam UMC, Vrije Universiteit Amsterdam; D.E. Beaton, PhD, Senior Scientist, Institute for Work & Health, and Associate Professor, Institute Health Policy, Management and Evaluation, University of Toronto; B.J. Shea, PhD, Senior Scientist, Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; L.J. Maxwell, PhD, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; S.J. Bartlett, PhD, Professor of Medicine, McGill University, Centre for Outcomes Research and Evaluation, and Division of Rheumatology, Department of Medicine, Johns Hopkins University; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre; M.A. D'Agostino, MD, PhD, AP-HP, Professor of Rheumatology, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, OMERACT Patient Research Partner, and Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam Public Health; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research, and Department of Rheumatology, Royal North Shore Hospital; J.A. Singh, MBBS, MPH, Professor of Medicine and Epidemiology, Department of Medicine at the School of Medicine, University of Alabama at Birmingham; L.S. Simon, MD, Co-Managing Director of SDG LLC; V. Strand, MD, Biopharmaceutical Consultant, Portola Valley, California, USA; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Professor, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute.
出版信息
J Rheumatol. 2019 Aug;46(8):1021-1027. doi: 10.3899/jrheum.181096. Epub 2019 Feb 15.
OBJECTIVE
The Outcome Measures in Rheumatology (OMERACT) Filter 2.0 framework was developed in 2014 to aid core outcome set development by describing the full universe of "measurable aspects of health conditions" from which core domains can be selected. This paper provides elaborations and updated concepts (OMERACT Filter 2.1).
METHODS
At OMERACT 2018, we discussed challenges in the framework application caused by unclear or ambiguous wording and terms and incompletely developed concepts.
RESULTS
The updated OMERACT Filter 2.1 framework makes benefits and harms explicit, clarifies concepts, and improves naming of various terms.
CONCLUSION
We expect that the Filter 2.1 framework will improve the process of core set development.
目的
关节炎疗效评价方法（OMERACT）筛选 2.0 框架于 2014 年制定，旨在通过描述可从中选择核心领域的“健康状况的可衡量方面”的整体范围，来帮助核心结局集的开发。本文提供了详细说明和更新的概念（OMERACT 筛选 2.1）。
方法
在 2018 年 OMERACT 会议上，我们讨论了框架应用中由于措辞和术语不明确或模棱两可以及概念不完整而导致的挑战。
结果
更新后的 OMERACT 筛选 2.1 框架明确了益处和危害，澄清了概念，并改进了各种术语的命名。
结论
我们期望筛选 2.1 框架将改进核心集开发过程。
Zotero 插件